Kaleido Biosciences, Inc.
KLDO · OTC
12/31/2021 | 9/30/2021 | 6/30/2021 | 3/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 373.1% | -50.7% | -29% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $16 | $17 | $18 | $17 |
| G&A Expenses | $5 | $5 | $6 | $5 |
| SG&A Expenses | $5 | $5 | $6 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | -$0 |
| Operating Expenses | $20 | $23 | $23 | $23 |
| Operating Income | -$20 | -$22 | -$23 | -$22 |
| % Margin | -4,003.9% | -21,551% | -10,998.6% | -7,524.6% |
| Other Income/Exp. Net | -$1 | -$1 | -$1 | -$1 |
| Pre-Tax Income | -$20 | -$23 | -$24 | -$23 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$21 | -$22 | -$25 | -$24 |
| % Margin | -4,292.5% | -21,626% | -11,655.5% | -7,994.9% |
| EPS | -0.001 | -0.53 | -0.58 | -0.6 |
| % Growth | 99.9% | 8.6% | 3.3% | – |
| EPS Diluted | -0.001 | -0.53 | -0.58 | -0.6 |
| Weighted Avg Shares Out | 42 | 43 | 43 | 40 |
| Weighted Avg Shares Out Dil | 42 | 43 | 43 | 40 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$19 | -$22 | -$23 | -$22 |
| % Margin | -3,852.2% | -20,944.2% | -10,711.4% | -7,325.3% |